Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fanelli, M.
Right arrow Articles by Pelicci, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fanelli, M.
Right arrow Articles by Pelicci, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 93 No. 5 (March 1), 1999: pp. 1477-1481

RAPID COMMUNICATION

Constitutive Degradation of PML/RAR&b.alpha; Through the Proteasome Pathway Mediates Retinoic Acid Resistance

By Mirco Fanelli, Saverio Minucci, Vania Gelmetti, Clara Nervi, Carlo Gambacorti-Passerini, and Pier Giuseppe Pelicci

From the European Institute of Oncology, the Department of Experimental Oncology, Milan; Istituto Nazionale Tumori, Divisione Oncologia Sperimentale D, Milan; Istituto di Clinica Medica I, University of Perugia, Perugia; and Universita' `La Sapienza," Istituto di Istologia, Rome, Italy.


    ABSTRACT
Top
Abstract
Introduction
References

PML/RARalpha is the leukemogenetic protein of acute promyelocytic leukemia (APL). Treatment with retinoic acid (RA) induces degradation of PML/RARalpha , differentiation of leukaemic blasts, and disease remission. However, RA resistance arises during RA treatment of APL patients. To investigate the phenomenon of RA resistance in APL, we generated RA-resistant sublines from APL-derived NB4 cells. The NB4.007/6 RA-resistant subline does not express the PML/RARalpha protein, although its mRNA is detectable at levels comparable to those of the parental cell line. In vitro degradation assays showed that the half-life of PML/RARalpha is less than 30 minutes in NB4.007/6 and longer than 3 hours in NB4. Treatment of NB4.007/6 cells with the proteasome inhibitors LLnL and lactacystin partially restored PML/RARalpha protein expression and resulted in a partial release of the RA-resistant phenotype. Similarly, forced expression of PML/RARalpha , but not RARalpha , into the NB4/007.6 cells restored sensitivity to RA treatment to levels comparable to those of the NB4 cells. These results indicate that constitutive degradation of PML/RARalpha protein may lead to RA resistance and that PML/RARalpha expression is crucial to convey RA sensitivity to APL cells.
© 1999 by The American Society of Hematology.


    INTRODUCTION
Top
Abstract
Introduction
References

ACUTE PROMYELOCYTIC leukemia (APL) is associated with the 15;17 chromosomal translocation which fuses the PML and retinoic receptor alpha  (RARalpha ) genes to yield a PML/RARalpha fusion protein.1,2 Transgenic mice studies showed that expression of PML/RARalpha results in altered myelopoiesis and development of leukemia, indicating a crucial role of the fusion protein in leukemogenesis.3-5

PML/RARalpha retains most of the functional domains of the RARalpha protein. In vitro studies showed that the DNA binding domain of the RARalpha component is indispensable for the property of the fusion protein to block differentiation of hematopoietic precursors.6 Altered regulation of RA target genes may, therefore, represent a fundamental mechanism of PML/RARalpha -mediated leukaemogenesis.

Pharmacological doses of RA induce disease remission in almost 90% APL cases by triggering terminal differentiation of leukemic blasts.7 RA induces degradation of the fusion protein through mechanisms that involve caspases8 and the proteasome pathway.9,10 Although PML/RARalpha degradation was initially suggested as the molecular cause of RA sensitivity, recent results suggest that PML/RARalpha expression is required to achieve RA sensitivity.8,11-13

Relapse and RA resistance arise after RA treatment of APL patients.1,2 Although the recent association of RA and chemotherapy resulted in a marked reduction of relapses,14 RA resistance of APLs remains an unresolved biological phenomenon.

Several RA-resistant sublines have been derived from the APL NB4 cell line.15-18 The NB4.007/6 subline was selected under the selective pressure of RA and is characterized by undetectable levels of PML/RARalpha protein.16 Because PML/RARalpha mRNA is present at comparable levels in NB4.007/6 and parental NB4 cells, we investigated the possible involvement of posttranslational regulatory pathways that could determine degradation of PML/RARalpha protein and RA resistance in NB4.007/6.


    MATERIALS AND METHODS

Cell culture and chemicals.   The APL NB4 cells, obtained from Dr M. Lanotte (INSERM, Paris, France), and NB4.007/6 RA-resistant cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS). All-trans retinoic acid and N-Acetyl-Leu-Leu-Norleucinal (LLnL) were obtained from Sigma (St Louis, MO). Anti-RARalpha antibody was obtained from Pierre Chambon (Institut de Chimie Biologique, Faculté de Médecine, Strasbourg, France).19 The anti-PML PG-M3 antibody has been described.20

In vitro degradation assay.   Cells were washed in phophate-buffered saline (PBS) and then lysed in NP40 buffer (50 mmol/L HEPES-pH 7.0, 250 mmol/L NaCl, 0.1% NP40, 5 mmol/L EDTA, 1 mmol/L dithiothreitol (DTT), 2 mmol/L phenylmethylsulfonyl fluoride (PMSF), 2 µg/mL leupeptin, 2 µg/mL aprotinin). NB4 and NB4.007/6 lysates were mixed (1:1) and incubated at 37°C. Reactions were stopped by addition of sodium dodecyl sulfate (SDS) sample buffer.

Western blotting.   The samples were resolved by 8% SDS polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto nitrocellulose filters. Western blots were performed as described.6

Transglutaminase activity assay.   TGase type II activity was performed as described.21

Infection of NB4 and NB4.007/6 cells.   The RARalpha and PML/RARalpha cDNAs were fused to the green fluorescent protein (GFP) cDNA sequence and then cloned in a hybrid Epstein-Barr virus (EBV)/retroviral vector.22 In the resulting construct, GFP-RARalpha or GFP-PML/RARalpha expression is driven by the LTR promoter. The packaging Phoenix cells were transfected by the calcium-phosphate/chloroquine method.22 The supernatant from the transfections, containing the viral particles, was collected after 48 hours, filtered, and then used to perform the infection of the target cells as described.22 Forty-eight hours after infection, cells were treated with 1 µmol/L RA to induce cell differentiation. After 5 days of RA treatment, cells were analyzed by fluorescent-activated cell sorter (FACS) for expression of differentiation markers. Immunophenotyping with alpha -cd11b and alpha -cd11c monoclonal antibodies was performed with formaldehyde fixation and a phycoerythrin-conjugated secondary antibody hybridization.


    RESULTS

Expression of the PML/RARalpha protein in the NB4.007/6 RA-resistant subline.   PML/RARalpha mRNA is detectable at comparable levels in NB4.007/6 and NB4 cells.15,16 Expression of PML/RARalpha protein in NB4.007/6 and parental NB4 cells was assessed by Western blot analysis. The anti-RARalpha antibody recognized a PML/RARalpha 116-kD band in NB4, but not in the NB4.007/6 cells (Fig 1A). To exclude the possibility that the fusion protein could lack the carboxy-terminal RARalpha F-domain recognized by the anti-RARalpha antibody, we tested other antibodies directed against different epitopes in the PML portion of the fusion protein (PG-M3 and PG, directed against the N-terminus and alpha -helix of the PML protein, respectively): PML/RARalpha truncated polypeptides were undetectable in the NB4.007/6 cells (data not shown). These results suggest the presence of degradative activity(ies) against PML/RARalpha in the NB4.007/6 subline. To test this hypothesis we measured the stability of the PML/RARalpha protein in cell extracts from NB4 and NB4.007/6. NB4 cell lysates were used as source of PML/RARalpha protein and then mixed with lysates of NB4.007/6 or NB4, as control. Western blot analysis of fusion protein expression in the NB4.007/6 lysates showed complete degradation of PML/RARalpha after 2 hours while, at the same time point, 60% of the fusion protein was still detected in the NB4 lysates (Fig 1B). The calculated half-life of PML/RARalpha is less than 30 minutes in lysates from NB4.007/6 cells and longer than 3 hours in the NB4-derived lysates, suggesting the presence of a degradative activity in NB4.007/6 cells that decreases PML/RARalpha stability. Notably, in vitro-translated PML/RARalpha was not degraded by the NB4.007/6 cell lysates, suggesting that posttranslational modification(s) is necessary for the degradation of the fusion protein (data not shown).


View larger version (34K):
[in this window]
[in a new window]
  		Fig 1. PML/RARalpha expression in NB4.007/6 cells. (A) Western blot analysis of NB4 and NB4.007/6 whole-cell lysates using an anti-RARalpha antibody. The immunoreactive polypeptide that migrates above the indicated PML/RARalpha in both cell lysates is an anti-RARalpha cross reactive cellular protein. (B) In vitro degradation of PML/RARalpha in NB4 and NB4.007/6 cell lysates: NB4 cell lysate or NB4.007/6 + NB4 mixed cell lysates were incubated as indicated and 20 µg (NB4; top panel) or 40 µg (NB4.007/6 + NB4; bottom panel) of proteins were resolved by SDS-PAGE and analyzed by Western blotting using an anti-RARalpha antibody.

Involvement of the proteasome pathway in both constitutive and RA-induced degradation of PML/RARalpha .   To investigate degradation of PML/RARalpha in vivo, we tested the effect of the proteasome inhibitors LLnL in NB4 and NB4.007/6 cells. NB4 cells were pretreated with 1 µmol/L RA for 6 hours, cultured in the presence or absence of 50 µmol/L LLnL for 12 hours, and analyzed by Western blotting at different time points. As previously described, RA treatment induced downregulation of PML/RARalpha protein and the appearance of an apparent degradation product of ~97 kD (Fig 2A). In contrast, RARalpha protein levels remained unchanged. The proteasome inhibitor LLnL blocked the RA-induced degradation of PML/RARalpha in NB4 cells (Fig 2A). LnLL was then tested in NB4.007/6 RA-resistant cells: a polypeptide reacting with the anti-RARalpha antibody and comigrating with PML/RARalpha was detected in NB4.007/6 upon LLnL treatment, although at a lower level than in NB4 cells (Fig 2B). Comparable results were obtained with another proteasome inhibitor (lactacystin; data not shown), suggesting that blocking of the proteasome pathway in NB4.007/6 cells partially restores PML/RARalpha expression. The fact that the effect of LLnL or lactacystin on PML/RARalpha expression was only partial, might be due to the short duration of treatment, because of its toxicity, or to the existence of additional PML/RARalpha degradation pathways in NB4.007/6 cells. We have recently shown that caspases are involved in RA-mediated degradation of PML/RARalpha in NB4 cells8 and that treatment with the caspase inhibitor ZVAD prevents this degradation. However, treatment of NB4.007/6 cells with ZVAD had no effects on PML/RARalpha expression, suggesting that caspases are not involved in the constitutive degradation of PML/RARalpha in these cells (data not shown).


View larger version (41K):
[in this window]
[in a new window]
  		Fig 2. Involvement of the proteasome in PML/RARalpha degradation. (A) NB4 cells were treated with 1 µmol/L RA in the presence (+LLnL) or in the absence (n.t.) of 50 µmol/L LLnL. The total lysates were resolved by SDS-PAGE and then analyzed by Western blotting using an anti-RARalpha antibody. The apparent degradation product of ~97 kD is shown by the arrowhead. (B) NB4.007/6 cells were treated with 50 µmol/L LLnL (+LLnL) or left untreated (n.t.). Lysates were blotted with anti-RARalpha antibody. A polypeptide comigrating with PML/RARalpha appeared after 9 and 12 hours of LLnL incubation (black arrow). (C) NB4 and NB4.007/6 cells infected with retroviruses expressing GFP alone (pinco) or GFP-PML/RARalpha (pinco-GFP-PR LTR) and were then analyzed by fluorescence microscopy for GFP localization. After 36 hours from infection with the PINCO-GFP-P/R LTR, the NB4 and NB4.007/6 cell lines showed the typical nuclear microspeckled pattern of PML/RARalpha (panels a and c). Both cell lines showed a diffuse distribution of the GFP protein upon infection with the PINCO control retrovirus (only shown for the NB4.007/6 cells; panel e). Panels b, d, and f show the corresponding DAPI staining. (D) NB4 and NB4.007/6 cells were infected with the pinco or the pinco-GFP-PR LTR retroviral vectors and variably treated with RA or LLNL, as indicated. Corresponding lysates were resolved by SDS-PAGE and then analyzed by Western blotting using anti-RARalpha , anti-GFP, and anti-beta -tubulin (to normalize for protein amounts loaded) antibodies, as indicated.

We next investigated in vivo the stability of an exogenous source of PML/RARalpha in NB4 or NB4.007/6 cells. To facilitate monitoring of ectopic protein expression, PML/RARalpha was fused to the green fluorescent protein (GFP).22 The resulting GFP-PML/RARalpha recombinant protein retains the same biological activities of the parental PML/RARalpha when expressed into U937 or 32D cells (our unpublished results, 1998). The GFP-PML/RARalpha cDNA was cloned under the control of the 5' LTR of a derivative of the hybrid EBV/retroviral PINCO vector22 (see Materials and Methods). NB4 and NB4.007/6 cells infected with the GFP-PML/RARalpha vector showed the typical micro-speckled expression pattern of PML/RARalpha (Fig 2C, panels a and c), while cells infected with the control vector (PINCO), encoding GFP alone, presented a diffuse signal (Fig 2C, panel e). To examine the stability of the fusion protein, we analyzed the GFP-PML/RARalpha expression by fluorescence microscopy and Western blotting. The efficiency of infection and the stability of the GFP protein from the control vector were identical in the NB4 and NB4.007/6 cell lines (data not shown). Instead, at 36 hours postinfection, the expression of the GFP-PML/RARalpha in NB4.007/6 cells was markedly lower than in NB4, decreased afterwards, and was undetectable 60 hours after, while GFP-PML/RARalpha expression in NB4 cells was stable up to several days postinfection (see Fig 2D for Western blots; fluorescence data are not shown). RA treatment induced degradation of the fusion protein in both cell lines with a proteasome-dependent mechanisms because it could be blocked by LLnL treatment (Fig 2D). Taken together, these results indicate that the proteasome pathway is involved in both RA-induced degradation of PML/RARalpha in NB4 cells and constitutive degradation of PML/RARalpha in NB4.007/6 cells.

To evaluate whether proteasome-dependent constitutive degradation of PML/RARalpha is a common event leading to RA resistance in APL cells, we evaluated the effects of LLnL or Lactacystin in the NB4.306 cell line. This is another, independently derived, RA-resistant cell line, which also expresses PML/RARalpha mRNA but no detectable protein.15 We did not observe any effect of the proteasome inhibitors on the steady-state levels of fusion protein expression in the NB4.306 cell line (data not shown).

Forced expression of PML/RARalpha restores RA sensitivity in NB4.007/6 cells.   We then tested whether restored PML/RARalpha expression in NB4.007/6 cells by LLNL was conducive to RA sensitivity. Since prolonged LLnL treatment leads to cell death of APL cells (data not shown), we could not evaluate terminal differentiation by examining canonical markers, such as cd11b or cd11c expression. Type II transglutaminase (TGII) activity is induced as an early event in NB4 cells during RA-mediated differentiation.21 Therefore, we examined the induction of TGII activity after RA and LLnL treatment in NB4 and NB4.007/6 cells. NB4.007/6 cells did not respond to RA, but in the presence of RA and LLnL we measured a significant increase in TGII activity (25% to 30% of the levels observed in NB4 cells; Fig 3A). These results suggest that the partial recovery of PML/RARalpha expression in NB4.007/6 cells after LLnL treatment partially restored RA sensitivity. To further support this interpretation, we analyzed the effect of RA in NB4.007/6 cells infected with the GFP-PML/RARalpha retroviral vector. As controls, cells were infected with retroviruses expressing GFP-RARalpha or the GFP alone. Comparable levels of exogenous protein expressions were obtained, as determined by FACS analysis of GFP expression (not shown). Infected cells were treated with RA for 5 days and then assayed for expression of the differentiation markers cd11b and cd11c by FACS analysis. Cells were gated according to GFP expression and GFP-positive cells only were considered for further analysis. In cells expressing GFP alone, RA did not induce CD11b and CD11c expression. In contrast, RA induced CD11b and CD11c expression in 31% and 40% of GFP-PML/RARalpha expressing NB4.007/6 cells, respectively. The RA response observed in GFP-PML/RARalpha cells was comparable to that measured in uninfected NB4 cells or NB4 cells infected with either control or the GFP-PML/RARalpha vectors. A partial RA response (10% to 15%) was observed in the GFP-RARalpha -expressing cells (Fig 3B). These results show that expression of PML/RARalpha in the RA-resistant NB4.007/6 cell line is sufficient to restore RA sensitivity and that capacity of the fusion protein to mediate RA signals into these RA-resistant cells is only partially exerted by RARalpha .


View larger version (21K):
[in this window]
[in a new window]
  		Fig 3. PML/RARalpha expression in NB4.007/6 cells restores RA sensitivity. (A) NB4 and NB4.007/6 cells were treated with RA for 12 hours and then further cultured in RA-containing medium, either in the presence or in the absence of 50 µmol/L LLnL, as indicated. At the end of treatment, TGase II activity was measured in the cellular extracts. (B) NB4.007/6 cells were infected with retroviruses expressing GFP alone (GFP), GFP-RARalpha (GFP-RAR), or GFP-PML/RARalpha (GFP-P/R) and then treated for 5 days with RA. At the end of the treatment, GFP-positive cells were analyzed for expression of the differentiation antigens cd11b and cd11c. The white bar (NB4) refers to the uninfected, control NB4 cells after 5 days of RA treatment. These results are derived from a single experiment of three that gave comparable results.


    DISCUSSION

The results presented here lead to two main conclusions: (1) in RA-resistant NB4.007/6 cells, PML/RARalpha expression is below detectable levels due to enhanced degradation of the fusion protein, and (2) forced expression of PML/RARalpha is sufficient to restore RA sensitivity in NB4.007/6 cells.

Constitutive degradation of PML/RARalpha in NB4.007/6 cells.   RA treatment of APL cells induces degradation of PML/RARalpha through mechanisms which involve both the proteasome and activated cellular caspases.8-10 Our results in NB4 and NB4.007/6 cells reinforce the view that the proteasome is a critical component of this process. NB4.007/6 cells were derived from NB4 cells under the selective pressure of continuous RA-treatment.9,10 The pathway of PML/RARalpha degradation in NB4.007/6 cells is RA independent and treatment with specific proteasome inhibitors increased the levels of PML/RARalpha , suggesting that the proteasome is responsible for the RA-independent degradation of PML/RARalpha in NB4.007/6 cells. Therefore, it appears that alteration(s) of the proteasome pathway leading to constitutive degradation of PML/RARalpha were selected in NB4.007/6 cells. However, proteasome inhibitors were unable to completely restore PML/RARalpha expression in the NB4.007/6 cells. Because caspases are not responsible for fusion protein degradation in these cells, a third pathway of proteolysis might be involved in the regulation of PML/RARalpha in the NB4.007/6 cells. Interestingly, constitutive degradation of PML/RARalpha did not lead to differentiation or to loss of the transformed phenotype in NB4.007/6 cells. We cannot rule out that PML/RARalpha is expressed below the detectable threshold in these cells, but at sufficient levels to mediate the differentiation block and/or the transformed phenotype. In this case, the resistance to RA would suggest that different levels of PML/RARalpha protein are required to mediate differentiation block/transformation and RA sensitivity. Alternatively, additional genetic events may have occurred during the establishment of the RA-resistant NB4.007/6 subline which resulted in a PML/RARalpha -independent phenotype. Indeed, NB4 cells carry additional chromosomal abnormalities with respect to those observed in fresh APL cells.23

PML/RARalpha expression restores RA sensitivity in the RA-resistant NB4.007/6 cells.   It has been proposed that PML/RARalpha degradation by RA is the key event underlying RA sensitivity of APL cells.9 The most striking result presented here is the observation that enhanced PML/RARalpha expression in the RA-resistant NB4.007/6 cells is sufficient to restore an RA-sensitive phenotype. This result suggests that the enhanced degradation of PML/RARalpha is the cause of RA resistance in NB4.007/6 cells. Notably, abnormal patterns of PML/RARalpha expression, including mutations, have been described in other RA-resistant sublines, as well as in the blasts from RA-resistant APL patients.16-18,24,25 NB4.007/6 cells, therefore, represent an in vitro system for the characterization of a phenomenon that may occur during the natural history of the disease; ie, appearance of RA-resistant cells as a consequence of enhanced degradation of PML/RARalpha .

The PML/RARalpha and RA-dependent differentiation observed in NB4.007/6 cells is the most direct confirmation of a recently proposed model, where PML/RARalpha expression is required to mediate RA sensitivity in APL cells. Because RA-induced degradation of PML/RARalpha is complete within 24 hours of RA treatment, PML/RARalpha may mediate the earliest steps required for RA-induced cell differentiation and natural RARalpha cannot substitute this function. Notably, NB4.007/6 cells express detectable levels of RXR protein (unpublished results, 1998).

The requirement for PML/RARalpha to achieve RA sensitivity in APL represents one of the paradoxes observed in this disease: supporting a dual role for the fusion protein, its expression is leukemogenetic at physiological concentrations of RA and then critical to mediate RA-induced differentiation at pharmacological doses of RA.


    ACKNOWLEDGMENT

We thank Edoardo Marchesi, Giardina Giuseppina, Cristian Matteucci, and Stefania Lupo for their excellent technical assistance.


    FOOTNOTES

Submitted July 28, 1998; accepted December 14, 1998.

C.G.-P. and P.G.P. contributed equally to this paper.

Supported by grants from Consiglio Nazionale Ricerche (CNR) to C.G.-P. and from Associazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Italiana per la Ricerca sul Cancro (FIRC) to P.G.P., C.G.-P., and S.M.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

Address reprint requests to Pier Giuseppe Pelicci, MD, European Institute of Oncology, Department of Experimental Oncology Via Ripamonti, 435-20141, Milan, Italy; e-mail: pgpelicci{at}ieo.cilea.it.


    REFERENCES
Top
Abstract
Introduction
References

1. Warrel RP Jr, de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993[Free Full Text]

2. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10, 1994[Free Full Text]

3. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARalpha under control of cathepsin G regulatory sequences. Blood 89:376, 1997[Abstract/Free Full Text]

4. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM: A PML/RARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551, 1997[Abstract/Free Full Text]

5. He L-Z, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94:5302, 1997[Abstract/Free Full Text]

6. Grignani Fr, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti I, Peschle C, Pelicci PG: Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of PML protein dimerization and RARalpha DNA binding domains. EMBO J 15:4949, 1996[Medline] [Order article via Infotrieve]

7. Chomienne C, Fenaux P, Degos L: Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 10:1025, 1996[Abstract]

8. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani Fr, Pelicci PG, Testi R: Caspases mediate retinoic acid induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92:2244, 1998[Abstract/Free Full Text]

9. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T: Accelerated degradation of PML-retinoic acid receptor alpha  (PML/RARalpha ) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteasome pathway. Cancer Res 56:2945, 1996[Abstract/Free Full Text]

10. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH Jr: The PML/RARalpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88:2826, 1996[Abstract/Free Full Text]

11. Grignani Fr, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML/RARalpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423, 1993[Medline] [Order article via Infotrieve]

12. Grignani Fr, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthard M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG: Fusion proteins of retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815, 1998[Medline] [Order article via Infotrieve]

13. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811, 1998[Medline] [Order article via Infotrieve]

14. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F: Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell' Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90:1014, 1997[Abstract/Free Full Text]

15. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, Marchesi E, Formelli F, Parmiani G, Pelicci PG, Gambacorti-Passerini C: Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RARalpha protein. Blood 82:1573, 1993[Abstract/Free Full Text]

16. Dermime S, Grignani F, Rogaia D, Liberatore C, Marchesi E, Gambacorti-Passerini C: Acute promyelocytic leukemia cells resistant to retinoic acid show further perturbation of the RARalpha signal transduction system. Leuk Lymphoma 16:289, 1995[Medline] [Order article via Infotrieve]

17. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner Ph, Berger R, Lanotte M: A retinoid acid `resistant' t(15;17) acute promyelocytic leukemia cell line: Isolation, morphological, and molecular features. Leukemia 6:1281, 1992[Medline] [Order article via Infotrieve]

18. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr: A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 89:4282, 1997[Abstract/Free Full Text]

19. Gaub MP, Lutz Y, Ruberte E, Petkovich M, Brand N, Chambon P: Antibodies specific to the retinoic acid human nuclear receptors alpha and beta. Proc Natl Acad Sci USA 86:3089, 1989[Abstract/Free Full Text]

20. Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Ferrucci PF, Martelli MF, Pelicci PG, Falini B: Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: Immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells and epithelia. Blood 85:1871, 1995[Abstract/Free Full Text]

21. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, Avvisati G, Gambacorti-Passerini C, Adamo S, Levin AA, Pelicci PG, Nervi C: Retinoid-induced differentiation of acute promyelocytic leukemia involves PML/RARalpha -mediated increase of type II transglutaminase. Blood 87:1939, 1996[Abstract/Free Full Text]

22. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F, Lanfrancone L, Peschle C, Nolan GP, Pelicci PG: High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 58:14, 1998[Abstract/Free Full Text]

23. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R: NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080, 1991[Abstract/Free Full Text]

24. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124, 1998[Abstract/Free Full Text]

25. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS, Wiernik PH, Gallagher RE: Leukemic cellular retinoic acid resistance and missence mutations in the PML/RAR alpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 92:1172, 1998[Abstract/Free Full Text]

© 1999 by The American Society of Hematology.
 
0006-4971/99/9305-0030$3.00/0

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
S. van Wageningen, M. C. Breems-de Ridder, J. Nigten, G. Nikoloski, C. A. J. Erpelinck-Verschueren, B. Lowenberg, T. de Witte, D. G. Tenen, B. A. van der Reijden, and J. H. Jansen
Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR{alpha}
Blood, February 1, 2008; 111(3): 1634 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Quere, A. Baudet, B. Cassinat, G. Bertrand, J. Marti, L. Manchon, D. Piquemal, C. Chomienne, and T. Commes
Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity
Blood, May 15, 2007; 109(10): 4450 - 4460.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. Carbone, O. A. Botrugno, S. Ronzoni, A. Insinga, L. Di Croce, P. G. Pelicci, and S. Minucci
Recruitment of the Histone Methyltransferase SUV39H1 and Its Role in the Oncogenic Properties of the Leukemia-Associated PML-Retinoic Acid Receptor Fusion Protein
Mol. Cell. Biol., February 15, 2006; 26(4): 1288 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood, February 15, 2005; 105(4): 1669 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Fanelli, A. Fantozzi, P. De Luca, S. Caprodossi, S.-i. Matsuzawa, M. A. Lazar, P. G. Pelicci, and S. Minucci
The Coiled-coil Domain Is the Structural Determinant for Mammalian Homologues of Drosophila Sina-mediated Degradation of Promyelocytic Leukemia Protein and Other Tripartite Motif Proteins by the Proteasome
J. Biol. Chem., February 13, 2004; 279(7): 5374 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Launay, M. Gianni, L. Diomede, L. M. Machesky, J. Enouf, and B. Papp
Enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into the endoplasmic reticulum: cross-talk between RARalpha and calcium-dependent signaling
Blood, April 15, 2003; 101(8): 3220 - 3228.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res., July 15, 2002; 62(14): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D.-C. Zhou, S. H. Kim, W. Ding, C. Schultz, R. P. Warrell Jr, and R. E. Gallagher
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo
Blood, February 15, 2002; 99(4): 1356 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Gianni', Y. Kalac, I. Ponzanelli, A. Rambaldi, M. Terao, and E. Garattini
Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RAR{alpha} and PML-RAR{alpha}
Blood, May 15, 2001; 97(10): 3234 - 3243.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Wang, X. Zheng, F. G. Behm, and M. Ratnam
Differentiation-independent retinoid induction of folate receptor type beta , a potential tumor target in myeloid leukemia
Blood, November 15, 2000; 96(10): 3529 - 3536.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Gambacorti-Passerini, R. Barni, P. le Coutre, M. Zucchetti, G. Cabrita, L. Cleris, F. Rossi, E. Gianazza, J. Brueggen, R. Cozens, et al.
Role of {alpha}1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
J Natl Cancer Inst, October 18, 2000; 92(20): 1641 - 1650.
[Abstract] [Full Text] [PDF]